Familial transthyretin amyloidosis (familiar ATTR amyloidosis) is a hereditary disease characterized by the deposition of amyloid proteins, especially transferrin (TTN), in various organs and tissues. This leads to progressive dysfunction of organs, especially the heart and peripheral nerves. The disease can manifest itself with various clinical symptoms due to the variety of systems and tissues affected, including neuropathies, cardiomyopathies and other serious conditions. It is often diagnosed at a late stage, which complicates the treatment process and has a very negative impact on the quality of life of patients.
History of the disease and interesting historical facts
The history of familial transthyretin amyloidosis begins in the late 19th century, when amyloid dilated cardiomyopathy was first described in 1886, but the name "amyloidosis" was introduced into literary circulation only later. One of the first examples of familial amyloidosis was a disease identified in Arabian tribes known for their specific genetic mutations. An interesting fact is that the disease remained in the shadow of more well-known forms of amyloidosis for a long time, and only in the 20th century, thanks to advances in genetics and molecular biology, the genetic basis of this condition began to be actively studied, which led to the discovery of the participation of transferritin in the pathogenesis of the disease.
Epidemiology
Familial transthyretin amyloidosis has different statistical data depending on the region and population. According to the data, the prevalence of this disease is about 10-15 cases per 100,000 people in populations with a high predisposition, such as residents of Scandinavian countries and some regions of Africa. In some gene pools, for example, the Mapuche people, the incidence rates can be significantly higher, reaching 50 cases per 100,000 people. In recent years, there has been an increase in interest in this pathology, which is associated with improved diagnostic methods.
Genetic predisposition to this disease
This type of amyloidosis is most often caused by mutations in the TTH gene, located on chromosome 18. Currently, more than 100 different mutations associated with the development of the disease are known. The most common mutations include amino acid substitutions such as Val30Met and Ala97Ser, which lead to a disruption in the stability of the transferrin structure. Inheritance of genetic predisposition occurs in an autosomal dominant manner, which implies the risk of transmitting the disease from a parent to a child with a probability of 50%.
Risk factors for the development of this disease
Risk factors for familial transthyretin amyloidosis include both genetic and uncontrollable factors.
- Heredity - presence of genetically determined forms of amyloidosis in the family history
- Ethnicity - increased risk in certain populations, such as Scandinavian peoples and some African tribes
- Age - the incidence increases with age, especially after 50 years
Some factors can aggravate the course of the disease, such as bad habits (smoking, alcoholism) and a sedentary lifestyle.
Diagnosis of this disease
Diagnosis of familial transthyretin amyloidosis involves a comprehensive approach using laboratory and instrumental methods. The main symptoms may vary, but often include:
- Sensory disturbances in the extremities
- Muscle pain and weakness
- Cardiac complaints (such as shortness of breath, edema)
Laboratory tests may reveal elevated levels of transferrin, and radiological techniques such as MRI and CT scans can help visualize amyloid deposits. An important aspect is performing a biopsy to determine the presence of amyloid deposits. Differential diagnosis should be made with other forms of amyloidosis, such as secondary amyloidosis and amyloidosis in multiple myeloma.
Treatment
Treatment of familial transthyretin amyloidosis is very complex and requires an individual approach. It may include:
- General treatment aimed at supporting organ function
- Pharmacological treatment aimed at slowing the progression of the disease
- Surgical treatment such as organ transplantation (heart, liver) in severe cases
- Other treatments, including physical rehabilitation and mental health support
Pharmacotherapy may include drugs aimed at stabilizing transferrin.
List of medications used to treat this disease
The list of pharmacological agents for the treatment of familial transthyretin amyloidosis covers several classes:
- Patisiran (Onpattro) - RNA interference-based therapy
- Tebentafusp (Tebentafusp) - anti-amyloid drugs
- Inotersen (Tegsedi) - therapy aimed at reducing the synthesis of transferritin
These drugs have proven themselves in clinical practice due to their ability to slow the progression of the disease and improve the quality of life of patients.
Disease monitoring
Monitoring the patient's condition with familial transthyretin amyloidosis is key to disease control and management. Monitoring steps typically include:
- Regular assessment of cardiovascular function
- Monitoring of neuropathies and other clinical manifestations
- Assessment of the level of transferrin in the blood
The prognosis of the disease may vary depending on the time of treatment, the condition of the organs and the presence of concomitant diseases. Possible complications include heart failure, kidney failure and significant impairment of peripheral nerve function.
Age-related features of the disease
The course of familial transthyretin amyloidosis can vary significantly depending on the age group. In older people, the disease may manifest more acutely and rapidly, while in patients under 50 years of age, symptoms may develop slowly and sometimes go unnoticed. In addition, children and adolescents often have milder forms of the disease with fewer complications, while adult patients exhibit a more threatening clinical picture.
Questions and Answers
- What are the main symptoms of familial transthyretin amyloidosis? The main symptoms include neuropathy, cardiomyopathy, organ dysfunction, dyspnea and edema.
- How is this disease diagnosed? Diagnosis is based on clinical observation, laboratory tests, cardiac ultrasound and biopsy.
- What treatment is available for this condition? Treatment includes drug therapy, surgical methods and rehabilitation treatment.
- Is it possible to prevent the development of the disease? Prevention of the disease is not possible; however, early detection and subsequent treatment can improve the quality of life of patients.
- What is the prognosis for patients with familial transthyretin amyloidosis? Prognosis varies, but early treatment and ongoing monitoring can significantly improve outcome.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov recommends that patients and their families be attentive to the first signs of the disease, such as shortness of breath, fatigue, pain in the limbs. Early contact with medical specialists and testing for familial amyloidosis can be a decisive factor in choosing a treatment strategy. It is especially important to lead an active lifestyle and monitor the condition of the heart, undergo regular examinations and follow the doctor's recommendations. A full understanding of one's condition and active participation in the treatment process can significantly improve the quality of life and prolong the active period for patients.
